» Articles » PMID: 30807573

The Per-patient Costs of HIV Services in South Africa: Systematic Review and Application in the South African HIV Investment Case

Overview
Journal PLoS One
Date 2019 Feb 27
PMID 30807573
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In economic analyses of HIV interventions, South Africa is often used as a case in point, due to the availability of good epidemiological and programme data and the global relevance of its epidemic. Few analyses however use locally relevant cost data. We reviewed available cost data as part of the South African HIV Investment Case, a modelling exercise to inform the optimal use of financial resources for the country's HIV programme.

Methods: We systematically reviewed publication databases for published cost data covering a large range of HIV interventions and summarised relevant unit costs (cost per person receiving a service) for each. Where no data was found in the literature, we constructed unit costs either based on available information regarding ingredients and relevant public-sector prices, or based on expenditure records.

Results: Only 42 (5%) of 1,047 records included in our full-text review reported primary cost data on HIV interventions in South Africa, with 71% of included papers covering ART. Other papers detailed the costs of HCT, MMC, palliative and inpatient care; no papers were found on the costs of PrEP, social and behaviour change communication, and PMTCT. The results informed unit costs for 5 of 11 intervention categories included in the Investment Case, with the remainder costed based on ingredients (35%) and expenditure data (10%).

Conclusions: A large number of modelled economic analyses of HIV interventions in South Africa use as inputs the same, often outdated, cost analyses, without reference to additional literature review. More primary cost analyses of non-ART interventions are needed.

Citing Articles

Economic Evaluation of Free Prevention of Mother-to-Child Transmissions (PMTCT) Services to Non-South African Women Living in South Africa.

Boachie M, Bhardwaj V, Mamabolo B, Mdewa W, Goldstein S, Hofman K Health Serv Insights. 2025; 18:11786329251316660.

PMID: 39959139 PMC: 11826849. DOI: 10.1177/11786329251316660.


Costs of home-delivered antiretroviral therapy refills for persons living with HIV: Evidence from a pilot randomized controlled trial in KwaZulu-Natal, South Africa.

Tseng A, Barnabas R, van Heerden A, Ntinga X, Sahu M PLOS Glob Public Health. 2025; 4(12):e0003368.

PMID: 39774195 PMC: 11684705. DOI: 10.1371/journal.pgph.0003368.


Ten-year health impact, economic impact and return on investment of the South African molecular diagnostics programme for HIV, tuberculosis and SARS-CoV-2.

Nichols B, de Nooy A, Cassim N, Hans L, da Silva M, Chetty K BMJ Glob Health. 2024; 9(12).

PMID: 39631789 PMC: 11624778. DOI: 10.1136/bmjgh-2024-015830.


Leveraging international stakeholders' experiences with oral PrEP costs to accelerate implementation of the monthly dapivirine vaginal ring: A qualitative study.

Heck C, Kripke K, Dam A, Torres-Rueda S, Bozzani F, Obermeyer C Health Res Policy Syst. 2024; 22(1):156.

PMID: 39587579 PMC: 11587620. DOI: 10.1186/s12961-024-01240-5.


Health impact, budget impact, and price threshold for cost-effectiveness of lenacapavir for HIV pre-exposure prophylaxis in eastern and southern Africa: a modelling analysis.

Wu L, Kaftan D, Wittenauer R, Arrouzet C, Patel N, Saravis A Lancet HIV. 2024; 11(11):e765-e773.

PMID: 39312933 PMC: 11519315. DOI: 10.1016/S2352-3018(24)00239-X.


References
1.
Galarraga O, Wirtz V, Figueroa-Lara A, Santa-Ana-Tellez Y, Coulibaly I, Viisainen K . Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- and middle-income countries. Pharmacoeconomics. 2011; 29(7):579-99. PMC: 3833352. DOI: 10.2165/11586120-000000000-00000. View

2.
Walensky R, Wood R, Ciaranello A, Paltiel A, Lorenzana S, Anglaret X . Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Med. 2011; 7(12):e1000382. PMC: 3014084. DOI: 10.1371/journal.pmed.1000382. View

3.
Bassett I, Govindasamy D, Erlwanger A, Hyle E, Kranzer K, van Schaik N . Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. PLoS One. 2014; 9(1):e85197. PMC: 3898963. DOI: 10.1371/journal.pone.0085197. View

4.
Siapka M, Remme M, Obure C, Maier C, Dehne K, Vassall A . Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countries. Bull World Health Organ. 2014; 92(7):499-511AD. PMC: 4121865. DOI: 10.2471/BLT.13.127639. View

5.
Chimbindi N, Bor J, Newell M, Tanser F, Baltussen R, Hontelez J . Time and Money: The True Costs of Health Care Utilization for Patients Receiving "Free" HIV/Tuberculosis Care and Treatment in Rural KwaZulu-Natal. J Acquir Immune Defic Syndr. 2015; 70(2):e52-60. PMC: 4748708. DOI: 10.1097/QAI.0000000000000728. View